FDA Label Expansions: Social media discussions highlight Vertex Pharmaceuticals' recent FDA approvals expanding eligibility for its cystic fibrosis drugs Alyftrek and Trikafta to nearly 95% of U.S. patients. Investors note this milestone adds about 800 more eligible individuals, bolstering the company's dominant franchise in the space. The sentiment leans optimistic amid steady revenue from these therapies.
Pipeline Advancements: Conversations also focus on progress in pain therapies targeting Nav1.7 and Nav1.8 channels, with potential combination approaches drawing interest. Gene editing innovations and novel cystic fibrosis treatments are praised as signs of a robust pipeline beyond core products. Participants express confidence in Vertex's innovation edge.
Analyst and Earnings Outlook: Despite minor target price adjustments, buy ratings persist, underscoring strong cash flows and growth potential. Ahead of quarterly earnings, traders anticipate updates on guidance and pipeline milestones. Overall discussions reflect a cautiously bullish tone.
Note: This discussion summary was generated from an AI condensation of post data.
Vertex Pharmaceuticals Insider Trading Activity
Vertex Pharmaceuticals insiders have traded $VRTX stock on the open market 63 times in the past 6 months. Of those trades, 0 have been purchases and 63 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:
- JEFFREY M LEIDEN (Executive Chairman) has made 0 purchases and 17 sales selling 137,073 shares for an estimated $60,942,656.
- AMIT SACHDEV (EVP Chief Patient & Ext Af Off) has made 0 purchases and 9 sales selling 60,459 shares for an estimated $28,377,385.
- CHARLES F JR WAGNER (EVP, CO & FO) has made 0 purchases and 3 sales selling 23,532 shares for an estimated $10,778,252.
- OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) has made 0 purchases and 7 sales selling 12,203 shares for an estimated $5,725,801.
- DUNCAN MCKECHNIE (EVP, Chief Commercial Officer) has made 0 purchases and 4 sales selling 9,980 shares for an estimated $4,865,010.
- JONATHAN BILLER (EVP and Chief Legal Officer) has made 0 purchases and 6 sales selling 7,925 shares for an estimated $3,795,904.
- EDWARD MORROW III ATKINSON (EVP, Chief Technical Ops. Off.) has made 0 purchases and 5 sales selling 7,767 shares for an estimated $3,598,634.
- MARK E. BUNNAGE (EVP, Chief Scientific Officer) has made 0 purchases and 4 sales selling 6,260 shares for an estimated $2,984,769.
- CARMEN BOZIC (EVP and CMO) has made 0 purchases and 2 sales selling 4,658 shares for an estimated $2,168,904.
- KRISTEN AMBROSE (SVP & Chief Accounting Officer) has made 0 purchases and 3 sales selling 1,956 shares for an estimated $914,567.
- JOY LIU (EVP and Chief Legal Officer) has made 0 purchases and 2 sales selling 1,870 shares for an estimated $881,684.
- SANGEETA N. BHATIA sold 266 shares for an estimated $133,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenues of $3.2B in Q4 2025. This is an increase of 9.55% from the same period in the prior year.
You can track VRTX financials on Quiver Quantitative's VRTX stock page.
Vertex Pharmaceuticals Congressional Stock Trading
Members of Congress have traded $VRTX stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:
- REPRESENTATIVE DAVID TAYLOR sold up to $15,000 on 01/29.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
Vertex Pharmaceuticals Hedge Fund Activity
We have seen 794 institutional investors add shares of Vertex Pharmaceuticals stock to their portfolio, and 685 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 8,547,690 shares (-74.0%) from their portfolio in Q4 2025, for an estimated $3,875,180,738
- PARNASSUS INVESTMENTS, LLC removed 1,648,433 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $747,333,584
- BLACKROCK, INC. added 1,498,942 shares (+6.7%) to their portfolio in Q4 2025, for an estimated $679,560,345
- VICTORY CAPITAL MANAGEMENT INC added 1,109,200 shares (+49.4%) to their portfolio in Q4 2025, for an estimated $502,866,912
- FMR LLC removed 1,091,172 shares (-33.0%) from their portfolio in Q4 2025, for an estimated $494,693,737
- WELLINGTON MANAGEMENT GROUP LLP removed 950,311 shares (-19.9%) from their portfolio in Q4 2025, for an estimated $430,832,994
- WINSLOW CAPITAL MANAGEMENT, LLC added 887,640 shares (+inf%) to their portfolio in Q4 2025, for an estimated $402,420,470
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Vertex Pharmaceuticals Analyst Ratings
Wall Street analysts have issued reports on $VRTX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 03/18/2026
- HC Wainwright & Co. issued a "Buy" rating on 02/13/2026
- Bernstein issued a "Outperform" rating on 01/12/2026
- Leerink Partners issued a "Outperform" rating on 12/29/2025
- Wells Fargo issued a "Overweight" rating on 12/10/2025
- UBS issued a "Buy" rating on 11/07/2025
To track analyst ratings and price targets for Vertex Pharmaceuticals, check out Quiver Quantitative's $VRTX forecast page.
Vertex Pharmaceuticals Price Targets
Multiple analysts have issued price targets for $VRTX recently. We have seen 19 analysts offer price targets for $VRTX in the last 6 months, with a median target of $548.0.
Here are some recent targets:
- Whitney Ijem from Canaccord Genuity set a target price of $437.0 on 04/30/2026
- Terence Flynn from Morgan Stanley set a target price of $612.0 on 04/10/2026
- Naz Rahman from Maxim Group set a target price of $575.0 on 03/18/2026
- Joon Lee from Truist Securities set a target price of $525.0 on 03/11/2026
- Andrew S. Fein from HC Wainwright & Co. set a target price of $641.0 on 03/10/2026
- Akash Tewari from Jefferies set a target price of $580.0 on 03/10/2026
- Ying Huang from B of A Securities set a target price of $598.0 on 03/10/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
